CD79A and COVID-19: In this study, we optimised and validated an in-house SARS-CoV-2 spike, RBD and nucleoprotein IgG, IgM and IgA binding antibody ELISA that is relevant for serosurveillance studies in populations primarily comprised of asymptomatic and mildly symptomatic COVID-19 cases (29).